All News
Low-Molecular Weight Heparin Does Not Reduce Pregnancy Complications
A Lancet meta-analysis has reviewed the preventative effects of low-molecular-weight heparin (LMWH) on placenta-mediated pregnancy complications include pre-eclampsia, late pregnancy loss, placental abruption, and birth of a small-for-gestational-age (SGA) neonate.
Read ArticleEffective Interferon-Free Regimen for HCV-Cryoglobulinemic Vasculitis
Rheumatologists have been challenged to treat hepatitis C virus (HCV)-induced rheumatic disease since discovery of the virus in 1989.
Read ArticleMy Take on New Ocular Screening Guidelines for Plaquenil
A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time).
Long-Term Outcomes of Aromatase Inhibitor Arthralgias
Aromatase inhibitors (AI) are often given in the setting of estrogen receptor-positive (ER+) breast cancer therapy.
Read ArticleRheumNow Week in Review – 7 October 2016
Dr. Jack Cush reviews highlights from the journals and news this week on RheumNow.com.
Read ArticleCDC Says Prevalence of Severe Joint Pain is Rising
The October 7th edition of MMWR reports that severe joint pain (SJP) has significantly risen from 10.5 million in 2012 to 27.2% in 2014, based on recent NHIS surveys.
Read ArticleBiosimilar Reports – October 2016
RheumNow will periodically review this subject with “Biosimilar Reports” providing updates, news, new publications, overview articles and research results impacting to biosimilar development and use.
Read ArticleInfection Rates Stable in JIA With Anti-TNF Therapy
Children with juvenile idiopathic arthritis (JIA) treated with biologic therapies were at no higher risk for hospitalized infections than those treated with methotrexate alone, But, higher rates were seen with anakinra in systemic JIA.
Read ArticleLupus Nephritis Therapies Reviewed
Singh and colleagues have published a systematic review and Bayesian network metaanalyses of clinical trials of immunosuppressive drugs and corticosteroids in patients with lupus nephriti.
Anti-IL-23 Guselkumab Beats Adalimumab in Severe Psoriasis
Management of moderate to severe plaque psoriasis has advanced significantly with FDA approved therapies capable of targeting TNF alpha, IL-17 and IL-12/23.
Read ArticleBUILD Study - Baricitinib Shows Rapid Efficacy and X-ray Protection
Baricitinib is an oral, small molecule, once-daily DMARD, that specifically inhibits Janus kinase 1 and 2 and is being developed for use in rheumatoid arthritis. With much of the developmental clinical trials completed, the drug is slated for review and potential approval near the end of the year.
Read ArticleRheumNow Week in Review – 30 September 2016
Three new FDA approvals, proteomics, cancer, infectious risk, nonadherence and disappointing clinical trial results covered in this RheumNow Week in Review.
Read ArticleNSAIDs Pose a Dose-Related Risk for Heart Failure Hospitalizations
BMJ has reported the results of a case-control study that analyzed the risk of hospitalization from heart failure associated with the use of NSAIDs amongst healthcare databases from four European countries (the Netherlands, Italy, Germany, and the United Kingdom).
Read ArticleNo Difference in Infection Rates Among SLE Drugs
Rates of serious infection and mortality among patients with systemic lupus erythematosus (SLE) did not depend on the immunosuppressive drug regimen they were on, investigators reported.
Read ArticleIlaris Gets FDA Approval for Rare Febrile Disorders
Ilaris was previously approved for use in systemic JIA and CAPS. The FDA has expanded this to include TRAPS, Hyper-IgD and FMF based on clinical trials.
Read ArticleFDA Approves New Amgen Biosimilar for Adalimumab
2016 has been a big year for biosimilars in rheumatology.
Read ArticleFDA Approves Stelara for Crohn's Colitis
The anti-IL-12/IL-23 inhibitor, Stelara (ustekinumab) has been FDA approved for the treatment of psoriasis and psoriatic arthritis. In the last week, the EMA's CHMP has recommended that the drug also be approved for use in Crohn's disease.
Read ArticleRestricting High Price Drugs - A Dangerous Trend?
Who makes billions in profits and millions in bonus monies? PBMs and insurers, thats who.
This week United Healthcare and Express Scripts announced new plans to restrict patient and prescriber access to popular, expensive, albeit FDA-approved, medications and biologics.
Who benefits, who loses?
Wearable Activity Trackers Don't Improve Weight Loss
JAMA has reported the results of a 24-month trial showing that obese individuals on a long-term healthy diet and exercise program do not have significantly more weight loss from using a wearable device that tracks their activity.
Read ArticleAfter the 1st TNF Inhibitor, a Non-TNF Biologic is Next Best
Most US rheumatologists use multiple TNF inhibitors before switching. A new French study suggests that "other-MOA", non-TNF biologics are more effective after failing a TNF inhibitor.
Read Article